Abstract: A combined disc-type cavitation structure for underwater navigation of an underwater vehicle has an underwater vehicle and a fairing. A plurality of cavitators having sequentially increased outer diameters are sequentially arranged in the fairing. A cavitator receiving groove matched with the cavitator located on the front side is arranged in the center of the front surface of the cavitator located on the rear side in every two adjacent cavitators. The plurality of cavitators can be integrated into a whole by means of the cavitator receiving groove. The cavitator located at the front-most end is a first cavitator, and the remaining cavitators are second cavitators. The first cavitator is connected to the underwater vehicle by means of a buffer. Each second cavitator is respectively connected to the underwater vehicle by means of a driving device configured to axially move the corresponding second cavitator.

Abstract: An adjustable cavitator structure has a cavitator disposed at a head end of the underwater vehicle. The cavitator has a cavitator body, a center of which is connected to the head center of the underwater vehicle through a damper. The front end of the cavitator body is detachably connected with a head fairing device. The cavitator body is of a double-layer structure including a first layer and a second layer. A plurality of cavitator disc face retractable sheets are installed on the first layer and the second layer and are evenly distributed around the axis of the cavitator body, and are slidably connected with the corresponding first layer or second layer. A buffer driving mechanism for driving the cavitator disc face retractable sheets to slide in a radial direction of the cavitator body is installed at the head end of the underwater vehicle.

Abstract: A transparent conductive substrate structure used for a thermoforming process includes a transparent cover plate and a touch sensing layer structure. The transparent cover plate includes a toughening layer on one side thereof. The touch sensing layer structure arranged on one surface of the toughening layer, and includes a first transparent conductive layer, a dielectric layer, a barrier layer, a second transparent conductive layer, and a buffer protective layer. Each transparent conductive layer is directly applied to the transparent cover plate, so that the thickness between the transparent conductive layers is below 1 ?m. The thickness between layers may be reduced to increase the sensitivity of the touch sensing layer structure. To prevent each transparent conductive layer and an electrode wire layer from breaking during the thermoforming process, the transparent conductive substrate structure is combined with the buffer protective layer to strengthen the structure of each transparent conductive layer.

Abstract: The present disclosure provides compounds of Formula (I); or a pharmaceutically acceptable salt thereof, wherein each of Ring A, Ring B, Ra, Rb, L, R1, R2, m, and n is defined herein, pharmaceutical compositions thereof, methods of inhibiting ROCK1 and/or ROCK2, and methods of treating a ROCK1- and/or ROCK2-mediated disease or disorder.

Abstract: Compositions, systems, kits, and methods are described herein for the modulation, and in particular the reduction or inhibition, of expression of the FLCN gene or the activity of FLCN protein in a cell, animal, or human subject. Compositions, systems, and methods disclosed herein can be used to prevent, ameliorate, or treat diseases, particularly neuromuscular or neurodegenerative diseases, retinal degeneration diseases, or other TDP-43 proteinopathies. Methods are described for the modulation, and in particular the reduction or inhibition of FLCN expression or activity, comprising the use of a modulator to regulate FLCN expression or activity. Methods are also described for the development, synthesis, and production of modulators, and for therapeutic treatment of TDP-43 proteinopathies such as ALS and other related disorders.

Abstract: Compositions, systems, and methods are described herein to modulate (reduce/inhibit) expression/activity of FNIP1 and/or FNIP2 (“FNIP1/FNIP2”) in a cell, animal or human subject, which can prevent, ameliorate, or treat diseases (neuromuscular or neurodegenerative diseases). Methods are described for modulating (reducing/inhibiting) FNIP1/FNIP2 expression/activity via a modulator to regulate FNIP1/FNIP2 expression/activity. Also included are compositions containing modulators that regulate FNIP1/FNIP2 expression/activity. Pharmaceutical compositions, kits, and methods of delivering compositions used in modulating, reducing, or inhibiting FNIP1/FNIP2 expression/activity are described. Methods to develop, synthesize, or produce modulators, and treat ALS and related disorders (TDP-43 proteinopathies, oxidative stress, obesity, anemia, or ischemic diseases) are provided.

Abstract: A transparent conductive substrate structure used for a thermoforming process includes a transparent cover plate and a touch sensing layer structure. The transparent cover plate includes a toughening layer on one side thereof. The touch sensing layer structure arranged on one surface of the toughening layer, and includes a first transparent conductive layer, a dielectric layer, a barrier layer, a second transparent conductive layer, and a buffer protective layer. Each transparent conductive layer is directly applied to the transparent cover plate, so that the thickness between the transparent conductive layers is below 1 ?m. The thickness between layers may be reduced to increase the sensitivity of the touch sensing layer structure. To prevent each transparent conductive layer and an electrode wire layer from breaking during the thermoforming process, the transparent conductive substrate structure is combined with the buffer protective layer to strengthen the structure of each transparent conductive layer.

Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable salts thereof, wherein Cy1, Cy2, Cy3, R, R1, R2, and R3 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which inhibiting ROCK1, ROCK2, or ROCK1/2 has a therapeutically useful role.

Abstract: A cancer treatment apparatus has a neutron source generating neutrons exiting through a surface of a moderator block and an elongated beam-shaping apparatus (BSA) having a length and a circular cross section of a diameter less than the length, the BSA joined at one end to and projecting orthogonally from the surface of the moderator block of the neutron source, the BSA having a conically shaped element at an end away from the moderator block, the conically shaped element declining in diameter in a direction away from the moderator block. Neutrons produced by the neutron source enter the BSA at the surface of the moderator block, travel the length of the BSA, and exit the BSA through an aperture at the end of the BSA away from the moderator block.

Abstract: A neutron generator has a neutron source generating an ion beam bombarding a Titanium target having a first diameter, the target embedded in a pre-moderator, emitting fast neutrons isotropically, a portion of the fast neutrons moderated in passing through the pre-moderator and exiting through a lowermost surface of the pre-moderator, and a plate of moderating material abutting the lowermost surface of the pre-moderator, the plate having an opening therethrough in a shape of a truncated cone with an axis aligning with direction of the ion beam, a depth, a major diameter of at the upper surface of the plate and a minor diameter at the lower surface of the plate, the opening forming a funnel through which neutrons pass. Neutrons enter the funnel and are to exit through the minor diameter of the funnel, providing a neutron beam with a spot size useful for neutron radiography.

Abstract: A treatment system for evaluating boron sources for boron neutron cancer therapy (BNCT) has a substantially square secondary moderator having a central treatment chamber for a subject; and four substantially identical neutron generators positioned around the substantially square secondary moderator with the axis of each acceleration chamber passing through the center of the treatment chamber.

Abstract: A Boron neutron cancer treatment system has a secondary moderator having a central treatment chamber for a subject, and eight substantially identical neutron generators, each comprising a pre-moderator block. The eight neutron generators are positioned around the secondary moderator with the axis of each acceleration chamber passing through the center of the treatment chamber, and with the angled sides of the neutron generators fully adjacent.

Abstract: A Boron neutron cancer treatment system has a central treatment chamber for a subject, with six substantially identical neutron generators each having an acceleration chamber, the generators positioned around a secondary moderator with the axis of each acceleration chamber passing through center of the treatment chamber, and with angled sides of the neutron generators fully adjacent.

Abstract: A Boron neutron cancer treatment system has a moderator chamber filled with liquid or granular moderator material except for a central treatment chamber, the moderator chamber having parallel upper and lower surfaces, and a plurality of modular neutron generators fully immersed in the liquid or granular moderator material of the moderator chamber.

Abstract: A Boron neutron cancer treatment system has a secondary moderator having a central treatment chamber for a subject, and eight substantially identical neutron generators, each comprising a pre-moderator block. The eight neutron generators are positioned around the secondary moderator with the axis of each acceleration chamber passing through the center of the treatment chamber, and with the angled sides of the neutron generators fully adjacent.

Abstract: A Boron neutron cancer treatment system has a secondary moderator having a central treatment chamber, and several generators, each comprising a pre-moderator block, an acceleration chamber, a vacuum pump engaging the acceleration chamber at a right angle, a plasma ion chamber opening into the acceleration chamber, a gas source providing deuterium gas to the plasma ion chamber, a microwave energy source ionizing the gas in the plasma ion chamber, a cylindrical primary isolation well extending into the pre-moderator block, a secondary isolation well surrounding the primary isolation well, and a water-cooled titanium target disk at a lower extremity of the isolation well. The neutron generators are positioned around the secondary moderator with the axis of each acceleration chamber passing through the center of the treatment chamber, and with the angled sides of the neutron generators fully adjacent.

Abstract: A treatment system for evaluating boron sources for boron neutron cancer therapy (BNCT) has a substantially square secondary moderator having a central treatment chamber for a subject; and four substantially identical neutron generators positioned around the substantially square secondary moderator with the axis of each acceleration chamber passing through the center of the treatment chamber.

Abstract: A Boron neutron cancer treatment system has a moderator chamber filled with liquid or granular moderator material except for a central treatment chamber, the moderator chamber having parallel upper and lower surfaces, and a plurality of modular neutron generators fully immersed in the liquid or granular moderator material of the moderator chamber.

Abstract: A Boron neutron cancer treatment system has a central treatment chamber for a subject, with six substantially identical neutron generators each having an acceleration chamber, the generators positioned around a secondary moderator with the axis of each acceleration chamber passing through center of the treatment chamber, and with angled sides of the neutron generators fully adjacent.

Abstract: A neutron generator has a pre-moderator block of moderating material, an acceleration chamber, a vacuum pump evacuating the acceleration chamber to a moderately high vacuum, a plasma ion chamber opening into the acceleration chamber through an ion extraction iris, a gas source providing deuterium gas to the plasma ion chamber, a microwave energy source ionizing the gas in the plasma ion chamber, a primary and a secondary isolation well extending into the pre-moderator block, a water-cooled titanium target disk positioned at a lower extremity of the primary isolation well, the target disk biased to a substantial negative DC voltage, and electrically grounded metal cladding covering surfaces of the pre-moderator block. Ions extracted through the ion extraction iris are accelerated to bombard the titanium target producing energetic neutrons that pass through and are moderated by the pre-moderator block.